Who is sponsoring NCT05515120?

NCT05515120 is sponsored by Instituto Mexicano del Seguro Social.

What drugs are being tested in NCT05515120?

Interventions in NCT05515120: Rivaroxaban 20 MG [Xarelto], Aspirin 300mg, Acenocoumarol Oral Tablet.

What condition does NCT05515120 study?

NCT05515120 studies Venous Thromboembolism, Anticoagulant-induced Bleeding, Venous Thromboses, Pulmonary Embolism.

Is NCT05515120 still recruiting?

NCT05515120 is currently completed. Last updated 25 August 2022.

Last reviewed 2022-08-25 · How we verify

NCT05515120

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events

Completed Phase 2, PHASE3 Last updated 25 August 2022

What this trial tests

Phase 2, PHASE3 trial testing Rivaroxaban 20 MG [Xarelto] in Venous Thromboembolism in 58 participants. Completed in 1 July 2022.

Timeline

3 January 2021

Primary endpoint
9 January 2022

1 July 2022

Quick facts

Lead sponsor	Instituto Mexicano del Seguro Social
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	58
Start date	3 January 2021
Primary completion	9 January 2022
Estimated completion	1 July 2022
Sites	1 location across Mexico

Drugs / interventions tested

Rivaroxaban 20 MG [Xarelto]
Aspirin 300mg — full drug profile →
Acenocoumarol Oral Tablet — full drug profile →

Conditions studied

Venous Thromboembolism — all drugs for Venous Thromboembolism →
Anticoagulant-induced Bleeding — all drugs for Anticoagulant-induced Bleeding →
Venous Thromboses — all drugs for Venous Thromboses →
Pulmonary Embolism — all drugs for Pulmonary Embolism →

Sponsor

Instituto Mexicano del Seguro Social — full company profile →

Who can join

Adults 18 to 74, any sex, with Venous Thromboembolism or Anticoagulant-induced Bleeding. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Venous thromboembolism affects around 10 million people per year worldwide, however, despite its high incidence, there is no systematic review or randomized trial focused on the treatment of patients with recurrent deep vein thrombosis (DVT) and/or or pulmonary embolism (PE) during anticoagulant treatment. The objective was to compare the use of Rivaroxaban plus Aspirin versus Acenocoumarol in patients with recurrent venous thromboembolism treated with rivaroxaban.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Outcomes of Different Regimens of Rivaroxaban and Aspirin in Cardiovascular Diseases: A Network Meta-Analysis.
Al-Salihi MM, Qureshi AI. · · 2025 · PMID 40429430 · DOI 10.3390/jcm14103437

Verify or expand the search:

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting

Other Instituto Mexicano del Seguro Social trials

Trials by the same sponsor.

NCT07536009 — "Effectiveness of a Telerehabilitation Program Versus a Conventional Rehabilitation Program in Patients With Subacromial · NA · not yet recruiting
NCT06632184 — Peritoneal Lavage Using Saline or Saline With Ondansetron for Pain Control After Laparoscopic Cholecystectomy · Phase 4 · active not recruiting
NCT07073846 — Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery. · Phase 4 · recruiting
NCT07406971 — Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke · Phase 2 · recruiting
NCT07134504 — Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico. · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05515120 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Mexicano del Seguro Social
Last refreshed: 25 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05515120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing